Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Conditions
Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult · Cervical Cancer · Colorectal Cancer · Esophageal Cancer · Esophageal Squamous Cell Carcinoma · Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Head and Neck Squamous Cell Carcinoma · Melanoma · Merkel Cell Carcinoma · Microsatellite Instability-High Solid Malignant Tumor · Mismatch Repair Deficient Solid Malignant Tumor · Microsatellite Instability-High Colorectal Cancer · Mismatch Repair Deficient Colorectal Cancer · Non-small Cell Lung Cancer · Renal Cell Carcinoma · Small Cell Lung Cancer · Squamous Cell Carcinoma · Urothelial Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Precision NextGen Oncology, Beverly Hills, California, United States
Contact: Principal Investigator (Kamlesh Sankhala, MD)OPN Healthcare, Inc, Glendale, California, United States
Contact: Principal Investigator (Vu Phan, MD)University of Southern California, Los Angeles, California, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Contact: Principal Investigator (Alexander Mohler, MD)Baylor, Scott and White Research Institute, Dallas, Texas, United States
Contact: Principal Investigator (Divya Mella, MD)Northwest Medical Specialties, Tacoma, Washington, United States
Contact: Principal Investigator (Jorge Chaves, MD)
Study leads
Tom Chen, MD, PhD
Study Chair
NeOnc Technologies
Josh Neman, PhD
Study Director
NeOnc Technologies Holdings, Inc.